Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim C.M. | - |
dc.contributor.author | Hwang S. | - |
dc.contributor.author | Keam B. | - |
dc.contributor.author | Yu Y.S. | - |
dc.contributor.author | Kim J.H. | - |
dc.contributor.author | Kim D.-S. | - |
dc.contributor.author | Bae S.H. | - |
dc.contributor.author | Kim G.-D. | - |
dc.contributor.author | Lee J.K. | - |
dc.contributor.author | Seo Y.B. | - |
dc.contributor.author | Nam S.W. | - |
dc.contributor.author | Kang K.J. | - |
dc.contributor.author | Buonaguro L. | - |
dc.contributor.author | Park J.Y. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Wang H.J. | - |
dc.date.available | 2020-04-06T06:43:36Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 2235-1795 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26324 | - |
dc.description.abstract | Background/Aim: Uniform treatment of hepatocellular carcinoma (HCC) with molecular targeted drugs (e.g., sorafenib) results in a poor overall tumor response when tumor subtyping is absent. Patient stratification based on actionable gene expression is a method that can potentially improve the effectiveness of these drugs. Here we aimed to identify the clinical application of actionable genes in predicting response to sorafenib. Methods: Through quantitative real-time reverse transcription PCR, we analyzed the expression levels of seven actionable genes (VEGFR2, PDGFRB, c-KIT, c-RAF, EGFR, mTOR, and FGFR1) in tumors versus noncancerous tissues from 220 HCC patients treated with sorafenib. Our analysis found that 9 responders did not have unique clinical features compared to nonresponders. A receiver operating characteristic curve evaluated the predictive performance of the treatment benefit score (TBS) calculated from the actionable genes. Results: The responders had significantly higher TBS values than the nonresponders. With an area under the curve of 0.779, a TBS combining mTOR with VEGFR2, c-KIT, and c-RAF was the most significant predictor of response to sorafenib. When used alone, sorafenib had a 0.7-3% response rate among HCC patients, but when stratifying the patients with actionable genes, the tumor response rate rose to 15.6%. Furthermore, actionable gene expression is significantly correlated with tumor response. Conclusions: Our findings on patient stratification based on actionable molecular subtyping potentially provide a therapeutic strategy for improving sorafenib's effectiveness in treating HCC. © 2020 The Author(s). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | S. Karger AG | - |
dc.relation.isPartOf | Liver Cancer | - |
dc.title | Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000530718700006 | - |
dc.identifier.doi | 10.1159/000504548 | - |
dc.identifier.bibliographicCitation | Liver Cancer | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85081318615 | - |
dc.citation.title | Liver Cancer | - |
dc.contributor.affiliatedAuthor | Kim Y.S. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Gene signature | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.